CNMD · XBRL financial data

CONMED financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (CNMD's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	862	1,011	1,045	1,245	1,307	1,375
Revenue from contracts with customers	862	1,011	1,045	1,245	1,307	1,375
Cost of goods and services sold	402	443	474	568	574	624
Gross profit	460	568	571	676	733	750
Research and development	40	44	47	53	54	56
Selling, general and administrative	374	415	454	503	478	592
General and administrative	—	—	96	111	117	132
Total operating expenses	414	458	501	556	533	648
Operating income (loss)	46	110	70	121	200	103
Interest expense	44	35	29	40	37	31
Income tax expense (benefit)	(8)	11	10	16	31	24
Net income (loss)	10	63	(81)	64	132	47
Earnings per share, basic USD per share	0.33	2.14	(2.68)	2.10	4.29	1.52
Earnings per share, diluted USD per share	0.32	1.94	(2.68)	2.04	4.25	1.51
Weighted average shares, basic millions of shares	29	29	30	31	31	31
Weighted average shares, diluted millions of shares	29	32	30	32	31	31

Fiscal years (CNMD's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	27	21	29	24	24	41
Accounts receivable	177	184	191	242	238	248
Inventory	195	232	332	318	347	356
Prepaid and other current assets	17	24	29	31	31	29
Total current assets	417	460	581	616	640	673
Property and equipment, net	111	109	116	121	116	113
Right-of-use asset	22	19	18	17	40	49
Goodwill	618	618	815	807	805	807
Total assets	1,752	1,766	2,298	2,300	2,306	2,326
Accounts payable	53	58	73	88	102	94
Total current liabilities	190	197	297	311	278	315
Lease liability, non-current	15	13	12	10	33	44
Total liabilities	1,043	981	1,552	1,466	1,344	1,293
Retained earnings	457	497	413	453	560	589
Total stockholders' equity	709	785	746	834	963	1,033
Total liabilities and equity	1,752	1,766	2,298	2,300	2,306	2,326
Common shares outstanding (cover page) millions of shares	29	29	30	31	31	31

Fiscal years (CNMD's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	10	63	(81)	64	132	47
Stock-based compensation	13	16	22	24	26	28
Net cash from operating activities	65	112	33	125	167	171
Purchases of property and equipment	13	15	22	19	13	20
Net cash from investing activities	(14)	(15)	(250)	(20)	(13)	(21)
Dividends paid	23	23	24	25	25	25
Net cash from financing activities	(52)	(102)	225	(110)	(151)	(136)
Net change in cash	2	(7)	8	(5)	0	16

SIC 3845 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3845 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
CONMED	48	336	49*	29.8M	—	Q3 FY26 10-QSep 30, 2026
Alphatec Holdings	80	221	19*	155.1M	—	Q3 FY26 10-QSep 30, 2026
Tandem Diabetes Care	63	255	(35)*	69.6M	13.2 quarters	Q2 FY26 10-QJun 30, 2026
Artivion	77	126	(1.3)*	48.8M	61.1 quarters	Q2 FY26 10-QJun 30, 2026
NovoCure	97	193	23	116.9M	—	Q3 FY26 10-QSep 30, 2026
Establishment Labs Holdings	71	68	(17)*	29.8M	4.3 quarters	Q2 FY26 10-QJun 30, 2026
Integra Lifesciences Holdings	252	411	96*	77.8M	—	Q3 FY26 10-QSep 30, 2026
AtriCure	187	154	30*	50.9M	—	Q3 FY26 10-QSep 30, 2026
Lemaitre Vascular	27	not reported	16*	22.9M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.